Effects of drug countermeasures for space motion sickness on working memory in humans.
Paule
Merle G
MG
Behavioral Toxicology Laboratories, Division of Neurotoxicology, HFT-132, USFDA's National Center for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079-9502, USA. mpaule@nctr.fda.gov
Chelonis
John J
JJ
Blake
Donna J
DJ
Dornhoffer
John L
JL
D000328:Adult; D000932:Antiemetics / Q000009:adverse effects* / Q000627:therapeutic use; D003072:Cognition Disorders / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008468:Meclizine / Q000009:adverse effects / Q000627:therapeutic use; D008569:Memory Disorders / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control; D008570:Memory, Short-Term / Q000187:drug effects* / Q000502:physiology; D009483:Neuropsychological Tests; D011398:Promethazine / Q000009:adverse effects / Q000627:therapeutic use; D012399:Rotation / Q000009:adverse effects; D012601:Scopolamine / Q000009:adverse effects / Q000627:therapeutic use; D018489:Space Motion Sickness / Q000188:drug therapy* / Q000503:physiopathology; D014722:Vestibule, Labyrinth / Q000187:drug effects* / Q000503:physiopathology
D000932:Antiemetics; D008468:Meclizine; D012601:Scopolamine; D011398:Promethazine; D008140:Lorazepam
NASA Discipline Neuroscience; Non-NASA Center